Two new studies have suggested that the controversial anti-smoking drug varenicline (Chantix) may also help people fight cocaine and alcohol addictions.
The first study, published this month in the journal Alcohol and Drug Dependence, was a nine-week clinical trial that included 37 people with cocaine addiction. Researchers at the University of Pennsylvania found that participants who took varenicline were half as likely to use cocaine — as measured by urine tests three times a week — as those given placebo.
Additionally the participants drank less alcohol while on varenicline. Further, in an experiment in which participants were given a choice between cocaine and money in varying sums, people taking varenicline valued cocaine less than those on placebo, suggesting that the quit-smoking drug made cocaine less rewarding.
The second study will soon be published in the Alcoholism: Clinical and Experimental Research. It involved 15 moderate to heavy social drinkers.
While taking varenicline, they, too, found their drug of choice to be less enjoyable and more unpleasant. This comports with anecdotal reports of smokers who have told researchers that they found alcohol less desirable and therefore
drank less while using varenicline to quit smoking.
“A single medication that could decrease the use of both substances would be ideal,” said Hugh Myrick, associate professor of psychiatry at the Medical university of South Carolina and co-author of the drinking study, said in a statement, noting that many people are addicted to both alcohol and cocaine.
But varenicline is not without a downside. It carries a black box warning from the FDA because of serious psychiatric side effects, including suicidal thoughts and behavior. One study found that people taking varenicline to quit smoking were eight times more likely to engage in suicidal or self-injuring behavior than those using nicotine-replacement treatments like the patch. Other
research has linked varenicline to an increased risk of heart problems in people with pre-existing cardiovascular
disease, although the risk-benefit calculation here is complicated by the fact that smoking carries far greater risk to the heart and blood vessels than varenicline.